Davanat: Final Phase II data

Final data from the U.S. and Israeli Phase II DAVFU-003 trial in 20 patients receiving Davanat plus 5-fluorouracil (5-FU) showed that median PFS was 8.4 weeks. Patients were dosed 4 times monthly with...